China Biopharm Registers High Growth Figures For First Quarter
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China Biopharmaceuticals saw a strong growth in revenues in the first quarter of 2008 on the back of increased sales from its subsidiary Erye Pharmaceuticals. The company released fiscal results for its first quarter ended March 31 on May 16
You may also be interested in...
China’s MOH-SFDA Merger: Analysts Weigh In
SHANGHAI - China has reorganized the Ministry of Health and put the State FDA under its jurisdiction. The State Council's institutional restructuring scheme was officially approved March 15 at the first session of the 11 National People's Congress held in Beijing
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
Need a specific report? 1000+ reports available
Buy Reports